Knopp posts data of KB-3061 working on KCNQ2 Epileptic Encephalopathy
Category: #health  By Mateen Dalal  Date: 2019-09-18
  • share
  • Twitter
  • Facebook
  • LinkedIn

Knopp posts data of KB-3061 working on KCNQ2 Epileptic Encephalopathy

KCNQ2 epileptic encephalopathies is a serious type of neonatal epileptic condition which manifests in newborn children during the first week if their lives. This disease is being addressed by various pharmaceutical companies across the globe trying their best to find an effective as well as cost efficient drug for treatment.

Knopp Biosciences LLC, a drug discovery and development firm specializing in researching therapies to treat neurological disorders, recently reported outcomes of preclinical experiments showcasing that KB-3061, a leading molecule in the ion channel platform of company, restored Kv7 potassium channels’ function in cells that were engineered to express the gene variants which cause KCNQ2 epileptic encephalopathy, commonly referred to as KCNQ2-EE, a rare neonatal disease.

The Chief Executive Officer of Knopp, Michael Bozik, M.D., presented the data at Epilepsy Precision Medicine Conference which was conducted between Sept. 16-17 in Washington. D.C. Bozik’s presentation included preclinical observations from experiments that took place in collaboration with the Associate Professor of Neurosciences, Neurology and Molecular & Human Genetics in the Baylor College of Medicine, Edward C. Cooper, M.D., Ph.D.

These experiments expand the pharmacology earlier reported for KB-3061, including the invitro nanomolar activity of molecule in wild type Kv7.2 or Kv7.3 potassium channels.

Dr. Bozik further added that cells that are transfected to stimulate three missense mutations that are highly-recurrent to the KCNQ2 gene showcased strong function suppression, as measured by significantly decreased potassium current in the mutated Kv7.2 channels.

When it was treated with KB-3061, the mutated channels functioning was fully restored, they were producing regular Kv7.2 channel current density.

Knopp is enhancing the KB-3061 development as potential precision medicine to treat KCNQ2-EE, a neonatal, genetically-defined disease that is linked with seizures starting after birth as well as profound developmental delay. This disease happens due to dominant-negative mutations present in KCNQ2 gene, which creates a potassium channel, Kv7.2, which is crucial for to early brain development.

Dr. Bozik stated that the data generated in cooperation with Dr. Cooper supports the approach of precision medical to KCNQ2-EE. Bozik added that the outcomes suggest that restoring back suppressed channel activity of Kv7.2 may improve the dysfunction caused due to the KCNQ2 gene mutations.

Earlier in May, Knopp presented positive preclinical outcomes of Neonatal Epilepsy Drug candidate for KCNQ2-neonatal epileptic encephalopathy at the Antiepileptic Drug and Device Trials XV Conference.

 

Source credit: https://knoppbio.com/news-and-events/knopp-biosciences-reports-data-demonstrating-restoration-of-function-by-kb-3061-in-cellular-model-of-gene-variants-causing-kcnq2-epileptic-encephalopathy

  • share
  • Twitter
  • Facebook
  • LinkedIn


About Author

Mateen Dalal    

Mateen Dalal

Mateen has completed his Bachelor’s degree in electronics and telecommunication engineering, post which he lent his proficiency to the industry, working as a quality and test engineer. Drawn intricately toward the field of content creation however, Mateen soon switc...

Read More

More News By Mateen Dalal

Mercedes-AMG Petronas F1 Team and AMD team-up for F1 2020
Mercedes-AMG Petronas F1 Team and AMD team-up for F1 2020
By Mateen Dalal

Mercedes-AMG Petronas F1 Team, and Advanced Micro Devices (AMD), a renowned semiconductor developer, have reportedly announced a new multi-year partnership agreement that has combined the two firms’ passion of for high performance, beginning fr...

Aduro begins trial of MK-5890 for non-small cell lung cancer treatment
Aduro begins trial of MK-5890 for non-small cell lung cancer treatment
By Mateen Dalal

The biopharmaceutical giant has also received a USD 10 million development milestone payment from Merck & CO. for the initiation of the trial A clinical-stage biopharmaceutical company, Aduro Biotech, Inc. recently announced to have ba...

TherapeuticsMD submits a New Drug Application to the FDA for BIJUVA®
TherapeuticsMD submits a New Drug Application to the FDA for BIJUVA®
By Mateen Dalal

TherapeuticsMD, Inc., an inventive pharmaceutical company that focuses on women healthcare, has recently announced that it has presented a New Drug Application (NDA) pre-approval efficacy supplement to the U.S. FDA (Food and Drug Administration) for ...